Patent ID: 11912782
Assignee: MEDIMMUNE LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of killing multiple myeloma cells comprising:
contacting multiple myeloma cells that express B-cell maturation antigen (BCMA) with an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against BCMA conjugated to a cytotoxin, wherein the monoclonal antibody comprises
(a) a heavy chain variable region comprising a complementarity determining region 1 (HCDR1) amino acid sequence of SEQ ID NO: 1, an HCDR2 amino acid sequence of SEQ ID NO: 2, and an HCDR3 amino acid sequence of SEQ ID NO: 3; and
(b) a light chain variable region comprising a complementarity determining region 1 (LCDR1) amino acid sequence of SEQ ID NO: 4, an LCDR2 amino acid sequence of SEQ ID NO: 5, and an LCDR3 amino acid sequence of SEQ ID NO: 6;

wherein the ADC binds to BCMA on the multiple myeloma cells and kills the multiple myeloma cells.